No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
XORTX Therapeutics Names Michael Bumby as CFO; U.S.-listed Shares Down 4%
XORTX Therapeutics Inc. Faces Financial Challenges
XORTX Initiates Precision Medicine Program
XORTX Surges 62% in U.S. Premarket as Peer-Reviewed Research Backs Company's Approach to Polycystic Kidney Disease
Stocks in Play: XORTX Therapeutics Inc.
XORTX Therapeutics Reprices Warrants Connected With U.S. IPO